ArticleJournal of medical virology2026
Morbidity and Mortality Among People Living With HTLV-1: A 30-Year Retrospective Analysis in a Brazilian Cohort.
Article in Journal of medical virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
HTLV-1 infection is a chronic condition associated with the development of malignancies, inflammatory, and neurological disorders. In this study, the causes of hospitalization and mortality were assessed in a cohort of 508 individuals living with HTLV-1 followed over a 30-year period. Overall mortality was 8.5% in this population and increased to 15% among patients with HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), a major neurological syndrome characterized by motor, sensory, and urinary dysfunction. Hospitalization was required by 147 participants of the cohort (28.9%), and this increased to 40.2% (121 of 301) among those with HAM/TSP. Patients were admitted at least once, with a mean of two admissions per patient. Hospitalization was associated with HAM/TSP, particularly the degree of motor disability and HIV coinfection. Infectious diseases were the leading cause of both hospitalization (66.7%) and death (69%), most commonly urinary tract infections, pneumonia, and infected pressure ulcers. In addition, mortality was also directly related to the intensity of motor impairment and the number of hospitalizations. HAM/TSP was associated with an increased risk of hospitalization and readmission. Additionally, greater motor impairment was linked to higher risks of both hospitalization and mortality, while elevated HTLV-1 PVL was found to contribute to an increased risk of death. In conclusion, these findings highlight the importance of prevention and timely management of secondary infections to reduce morbidity and mortality in individuals living with HTLV-1, particularly those affected by HAM/TSP, which frequently present urinary dysfunction and pressure ulcers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.